Trial Profile

ReACH (Reduced Intensity Allografting for Chemosensitive Hodgkin Lymphoma): Phase II study of reduced intensity sibling allogeneic transplantation for relapsed, chemosensitive, PET positive Hodgkin lymphoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Aug 2013 Biomarkers information updated
21 Jun 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
31 May 2012 United Kingdom Clinical Research Network reports accrual date changed from 4% to 6%.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com